2/3, 8:23 AM (Source: TeleTrader)
more TeleTrader news

GSK, CureVac to develop 'next generation' mRNA COVID-19 vaccines

GlaxoSmithKline plc (GSK) and CureVac NV announced on Wednesday that the companies will work jointly on "next generation mRNA" vaccines against coronavirus in a plan worth €150 million.

In addition, GSK will assist in the production of "100 million doses of CureVac's first generation COVID-19 vaccine candidate CVnCoV in 2021."

"The aim of this work is to offer broader protection against a variety of different SARS-CoV2 variants, and to enable a quick response to new variants potentially emerging in the future. The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval," the companies pointed out in a statement.

Breaking the News / MS